Bristol-Myers Squibb Co, Zai Laboratory deal

Bristol-Myers granted Zai exclusive rights to develop, commercialize and manufacture oral brivanib in China, including Hong Kong and Macau, for oncology indications. BMS discontinued global development of brivanib in 2012 after it missed the primary endpoint of non-inferiority to sorafenib in improving overall survival (OS) in the Phase III BRISK-FL trial to treat hepatocellular carcinoma (HCC). The pharma said it does not have immediate plans to develop brivanib outside of China (see BioCentury, July 23, 2012). ...